HLA-C and neoplasm: Given the fact that Raji cells were not engineered to downregulate HLA-I expression, the most likely explanation for the observed tumour rejection in mice that did not receive blinatumomab is that there was an alloreactive T-cell response against the MHC-mismatched Raji-tumour cell line.